Cargando…
Hepatic iron overload, a possible consequence of treatment with imatinib mesylate: a case report
Imatinib, a tyrosine kinase inhibitor has revolutionized the therapy of Philadelphia chromosome positive chronic myeloid leukemia. Side effects of imatinib include grade 1-4 hepatotoxicity in a subset of patients. We report the case of a 46-year-old male with chronic myeloid leukemia, who developed...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Cases Network Ltd
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2740313/ https://www.ncbi.nlm.nih.gov/pubmed/19829996 http://dx.doi.org/10.1186/1757-1626-2-7526 |
_version_ | 1782171704302239744 |
---|---|
author | Maiti, Baidehi Setrakian, Sebouh Daw, Hamed A |
author_facet | Maiti, Baidehi Setrakian, Sebouh Daw, Hamed A |
author_sort | Maiti, Baidehi |
collection | PubMed |
description | Imatinib, a tyrosine kinase inhibitor has revolutionized the therapy of Philadelphia chromosome positive chronic myeloid leukemia. Side effects of imatinib include grade 1-4 hepatotoxicity in a subset of patients. We report the case of a 46-year-old male with chronic myeloid leukemia, who developed hepatic hemosiderosis during treatment with imatinib. After ruling out the established congenital and acquired causes of hepatic hemosiderosis, we attribute this to a possible side effect of imatinib therapy. This condition was successfully treated with periodic phlebotomy thus precluding discontinuation of imatinib. To our knowledge, this is the first report of hepatic hemosiderosis most likely consequent to imatinib therapy. |
format | Text |
id | pubmed-2740313 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Cases Network Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-27403132009-10-14 Hepatic iron overload, a possible consequence of treatment with imatinib mesylate: a case report Maiti, Baidehi Setrakian, Sebouh Daw, Hamed A Cases J Case report Imatinib, a tyrosine kinase inhibitor has revolutionized the therapy of Philadelphia chromosome positive chronic myeloid leukemia. Side effects of imatinib include grade 1-4 hepatotoxicity in a subset of patients. We report the case of a 46-year-old male with chronic myeloid leukemia, who developed hepatic hemosiderosis during treatment with imatinib. After ruling out the established congenital and acquired causes of hepatic hemosiderosis, we attribute this to a possible side effect of imatinib therapy. This condition was successfully treated with periodic phlebotomy thus precluding discontinuation of imatinib. To our knowledge, this is the first report of hepatic hemosiderosis most likely consequent to imatinib therapy. Cases Network Ltd 2009-05-26 /pmc/articles/PMC2740313/ /pubmed/19829996 http://dx.doi.org/10.1186/1757-1626-2-7526 Text en © 2009 Maiti et al.; licensee Cases Network Ltd. http://creativecommons.org/licenses/by/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case report Maiti, Baidehi Setrakian, Sebouh Daw, Hamed A Hepatic iron overload, a possible consequence of treatment with imatinib mesylate: a case report |
title | Hepatic iron overload, a possible consequence of treatment with imatinib mesylate: a case report |
title_full | Hepatic iron overload, a possible consequence of treatment with imatinib mesylate: a case report |
title_fullStr | Hepatic iron overload, a possible consequence of treatment with imatinib mesylate: a case report |
title_full_unstemmed | Hepatic iron overload, a possible consequence of treatment with imatinib mesylate: a case report |
title_short | Hepatic iron overload, a possible consequence of treatment with imatinib mesylate: a case report |
title_sort | hepatic iron overload, a possible consequence of treatment with imatinib mesylate: a case report |
topic | Case report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2740313/ https://www.ncbi.nlm.nih.gov/pubmed/19829996 http://dx.doi.org/10.1186/1757-1626-2-7526 |
work_keys_str_mv | AT maitibaidehi hepaticironoverloadapossibleconsequenceoftreatmentwithimatinibmesylateacasereport AT setrakiansebouh hepaticironoverloadapossibleconsequenceoftreatmentwithimatinibmesylateacasereport AT dawhameda hepaticironoverloadapossibleconsequenceoftreatmentwithimatinibmesylateacasereport |